Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: ABVC

ABVC BioPharma, Inc.

Healthcare | Biotechnology
$1.29 +0.03 (+2.38%) as of 2026-07-14 17:55 UTC
Market Cap$30M
Volume431.2K
EPS (TTM)$-0.39

ABVC BioPharma, Inc. (NASDAQ: ABVC) is a $30M biotechnology company trading at $1.29 (+2.4% today). Figures from SEC EDGAR and market feeds; updated 2026-07-14 17:55 UTC.

52-Week Range
Low $0.88High $5.48

What ABVC BioPharma, Inc. does

The company develops pharmaceutical and medical device candidates, primarily in oncology and ophthalmology. In oncology, the company is preparing Phase II clinical trials for ABV-1702 to treat myelodysplastic syndrome in combination with an approved drug, and has FDA approval to begin Phase II trials for ABV-1703 for pancreatic cancer; it also has an approved IND application for ABV-1501 for triple negative breast cancer combination therapy. In ophthalmology, the company completed a Phase I clinical trial for ABV-1701, a vitreous substitute, which showed positive results.

Summarized from ABVC BioPharma, Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
Key facts
Quote
Price$1.29
Change (1D)+0.03 (+2.38%)
Market cap$30M
Volume431.2K shares
52-week range$0.88 – $5.48
Valuation
EPS (TTM)$-0.39
Price/book2.70×
Debt/equity0.07
Returns
52-week return+46.6%
Revenue, margins & earnings
FY2021: net loss $13M on revenue $355,797$355,797FY2021FY2022: net loss $16M on revenue $969,783$969,783FY2022FY2023: net loss $8M on revenue $152,430$152,430FY2023FY2024: net loss $5M on revenue $509,589$509,589FY2024FY2025: net loss $8M on revenue $296,000$296,000FY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity
No insider transactions on file with the SEC for ABVC.
Source: SEC EDGAR · Last checked 2026-07-14
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • VANGUARD GROUP INC287,937$613.3K+7.7%
  • GEODE CAPITAL MANAGEMENT, LLC221,169$214.6K+9.3%
  • VANGUARD CAPITAL MANAGEMENT LLC190,574$184.9KNEW
View QoQ ownership changes →
Company news View all →
No qualifying company news in the archive. Full tape in the platform →
Questions this page answers

What does ABVC BioPharma, Inc. do?

The company develops pharmaceutical and medical device candidates, primarily in oncology and ophthalmology.

What is ABVC's valuation?

ABVC trades at $1.29, as of 2026-07-14.

When did ABVC last file with the SEC?

ABVC BioPharma, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 17:55 UTC. This page is also available as JSON at /api/data?ticker=ABVC and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for ABVC and 3,500+ tickers.

Create a free account — keep ABVC
For your agent
GET /api/data?ticker=ABVC

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt